EXOZYMES INC. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Trading Equity Our shares of Common Stock currently are quoted on Nasdaq under the symbol “EXOZ .” From November 11, 2024, when we completed our IPO, our Common Stock was quoted on Nasdaq under the symbol “IZTC.” When we changed our corporate name on February 10, 2025, to eXoZymes Inc., the trading symbol was changed. As of March 12, 2025, we had approximately 757 shareholders of record of the Common Stock and we believe over 739 shareholders who hold their shares of Common Stock in street name. Distributions We have not paid any dividends or made any distributions related to our equity securities, to date. Whether any distributions, the kinds of distributions, and the value of distributions are made in the future will depend on many factors and will be determined by the management of eXoZymes, from time to time. Investors should not look to any distribution that we might make to be a regular income item in an investor’s portfolio. We anticipate that any income will be retained and used in our operations. Use of Proceeds eXoZymes completed its initial public offering of shares of Common Stock on November 11, 2024, pursuant to the Registration Statement #333-276987. Each share of Common Stock was sold at a public offering price of $8.00, and the Company raised a gross amount of $15,901,328 and net proceeds of $15,206,543. Since the initial public offering on November 11, 2024, the Company has used approximately $5,149,980 of the net proceeds. Approximately (i) $4,243,022 was paid to MDB Capital Holdings LLC for related party loans that were used to support our operations in 2024, (ii) $143,615 was used to purchase additional lab equipment, which enhanced the labs operational capabilities, and (iii) $763,343 was disbursed for working capital. 28 Securities Authorized for Issuance Under Equity Compensation Plans Plan category Number of securities to be issued upon exercise of outstanding awards Weighted-average exercise price of outstanding awards Number of securities remaining available for future issuance under equity compensation plans 2020 Equity Incentive Award Plan, approved by security holders* 2,172,445 ** $ 4.66 317,022 Equity award plans not approved by security holders - - - Total 2,172,445 ** $ 4.66 31,022 * The 2020 Equity Incentive Award Plan provides for awards for up to 2,489,467 shares of shares of Common Stock. As of December 31, 2024, there are a total of 317,022 shares of Common Stock available for issuance. ** As of December 31, 2024, of the 2,172,445 securities to be issued upon exercise and vesting of awards, 1,747,789 represent share options with a weighted average exercise price of $4.66 and 424,656 represent Restricted Stock Unit awards which do not require payment of an exercise price. The Restricted Stock Unit awards are not included in the calculation of the weighted average exercise price above. Item 6. Selected Financial Data We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and therefore we are not required to provide the information under this item.